Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

U

University of South Carolina

Other

0

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

0

Indications↗

Distinct diseases across all programs

23

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Evaluating a Remotely Delivered Physical Activity Program for Inactive Men in Rural Communities: A Feasibility Study

Active, not recruiting

Physical Activity and Weight Loss to Improve Function and Pain After Total Knee Replacement

Nurturing, Empowering, Supporting Together (NEST): a Project to Improve Postpartum Birth Outcomes in the NICU.

Earlier

Oct 2, 2026TrialEcological Momentary Assessment of Smoking Triggers, Needs, and Cigarette Forgoing

Sep 24, 2026TrialDietary Insights and Nutritional Education in Adults on GLP-1 Therapy

Sep 23, 2026TrialIdentifying the Ideal Dose of Structured Summer Programming for Mitigating Accelerated Summer BMI Gain

Sep 23, 2026TrialIncreasing Low-income Children's Access to Healthy Structured Programming to Reduce Obesity

Sep 19, 2026TrialImproving the Collaborative Health of Adults With Chronic Conditions & Carepartner Dyads Through Interventions Addressing Social and Health Self-Management Needs.

4 more events

Aug 21, 2026TrialUse of a Cloud-connected Remote Blood Pressure Monitoring Program During the Postpartum Period for Hypertensive Women

Aug 12, 2026TrialLeveraging Digital Tools to Increase COVID-19 Vaccine Adoption

Aug 12, 2026TrialLeveraging Digital Tools to Increase COVID-19 Vaccine Adoption

Aug 11, 2026TrialBuilding on the Dietary Guidelines: 3 Dietary Pattern (DG3D) Study - Testing a Teaching Kitchens and Food is Medicine Approach for Type 2 Diabetes Prevention

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)